Affimed (NASDAQ:AFMD) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Affimed (NASDAQ:AFMD) in a report published on Thursday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Affimed Price Performance

AFMD stock opened at $0.73 on Thursday. The stock’s 50 day moving average is $0.86 and its two-hundred day moving average is $1.76. Affimed has a 52-week low of $0.52 and a 52-week high of $8.95. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.93 and a current ratio of 1.93.

Institutional Trading of Affimed

Several institutional investors have recently added to or reduced their stakes in AFMD. Northern Trust Corp acquired a new stake in shares of Affimed in the 4th quarter valued at about $218,000. Intellectus Partners LLC raised its stake in Affimed by 34.0% during the fourth quarter. Intellectus Partners LLC now owns 126,414 shares of the biopharmaceutical company’s stock valued at $150,000 after buying an additional 32,053 shares in the last quarter. Jane Street Group LLC bought a new position in Affimed during the 3rd quarter worth approximately $44,000. Finally, FMR LLC grew its position in shares of Affimed by 30.0% in the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after acquiring an additional 4,086 shares in the last quarter. 30.82% of the stock is owned by institutional investors and hedge funds.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.